Filing Flows › Profound Medical (PROF) › Takeover & LBO
Is Profound Medical (PROF) a takeover target?
A leveraged buyout does not work for Profound Medical on its latest figures: it has no positive EBITDA to borrow against (−$35.0M over the last 12 months, on revenue of $19.1M).
Why a leveraged buyout does not fit
A leveraged buyout is paid for mostly with debt that the company's own cash flow repays. Profound Medical's EBITDA over the last 12 months was −$35.0M on revenue of $19.1M, so there is nothing to lend against and nothing to repay a loan with: a buyer would have to pay almost entirely with its own money. That is the kind of deal another company — a strategic buyer that wants the products, the pipeline or the technology — makes, not a private-equity fund. The model therefore gives no buyout price.
What a takeover could cost
Takeovers in its sector paid a median premium of 35% over the share price before the deal (the middle half 22% to 45%), according to the 15 merger proxies and tender-offer responses on EDGAR that state a premium. At the median, Profound Medical would cost about $9.79 a share, $356M for all its shares.
| Premium | % | Price a share | All shares |
|---|---|---|---|
| Low end (a quarter of deals paid less) | 22% | $8.85 | $322M |
| Median | 35% | $9.79 | $356M |
| High end (a quarter paid more) | 45% | $10.51 | $382M |
Profound Medical's latest quarter
Profound Medical, Q3 2026: revenue $9.8M (+86% year over year), operating margin -79.6%, net loss $7.7M, operating cash flow −$5.0M. The chart follows the revenue to costs, profit and cash.
Questions
Is Profound Medical being acquired?
No headline, 8-K or 13D about a sale is on file in the last year.
Could private equity buy Profound Medical?
A leveraged buyout does not work for Profound Medical on its latest figures: it has no positive EBITDA to borrow against (−$35.0M over the last 12 months, on revenue of $19.1M). With no cash flow to repay a loan, a buyer would pay almost entirely with its own money: a deal for another company (a strategic buyer), not for a private-equity fund.
What would a takeover of Profound Medical cost?
Takeovers in its sector paid a median premium of 35% over the share price before the deal (the middle half 22% to 45%), according to the 15 merger proxies and tender-offer responses on EDGAR that state a premium. At the median, Profound Medical would cost about $9.79 a share, $356M for all its shares.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.